Considering our results on CTLA-4 expression in the immune cell microenvironment and the availability of targeted drugs such as Ipilimumab, which acts through CTLA-4 blockade, it may be relevant to explore this as a targeted therapy for HL cases, particularly for those with refractory disease unable to achieve disease cure before ASCT, for patients relapsing after ASCT, and for whom no further curative options are currently available. This evidence concerns the gene CTLA4 and Hodgkins lymphoma.